You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia
|
|---|---|
| Published in |
The Pharmacogenomics Journal, January 2015
|
| DOI | 10.1038/tpj.2014.81 |
| Pubmed ID | |
| Authors |
J Gregers, H Gréen, I J Christensen, K Dalhoff, H Schroeder, N Carlsen, S Rosthoej, B Lausen, K Schmiegelow, C Peterson |
| Abstract |
The membrane transporter P-glycoprotein, encoded by the ABCB1 gene, influences the pharmacokinetics of anti-cancer drugs. We hypothesized that variants of ABCB1 affect outcome and toxicity in childhood acute lymphoblastic leukemia (ALL). We studied 522 Danish children with ALL, 93% of all those eligible. Risk of relapse was increased 2.9-fold for patients with the 1199GA variant versus 1199GG (P=0.001), and reduced 61% and 40%, respectively, for patients with the 3435CT or 3435TT variants versus 3435CC (overall P=0.02). The degree of bone marrow toxicity during doxorubicin, vincristine and prednisolone induction therapy was more prominent in patients with 3435TT variant versus 3435CT/3435CC (P=0.01/P<0.0001). We observed more liver toxicity after high-dose methotrexate in patients with 3435CC variant versus 3435CT/TT (P=0.03). In conclusion, there is a statistically significant association between ABCB1 polymorphisms, efficacy and toxicity in the treatment of ALL, and ABCB1 1199G>A may be a new possible predictive marker for outcome in childhood ALL.The Pharmacogenomics Journal advance online publication, 13 January 2015; doi:10.1038/tpj.2014.81. |
Mendeley readers
The data shown below were compiled from readership statistics for 103 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 3 | 3% |
| Serbia | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 98 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 24 | 23% |
| Researcher | 14 | 14% |
| Student > Master | 13 | 13% |
| Student > Bachelor | 8 | 8% |
| Student > Postgraduate | 7 | 7% |
| Other | 14 | 14% |
| Unknown | 23 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 25% |
| Biochemistry, Genetics and Molecular Biology | 16 | 16% |
| Agricultural and Biological Sciences | 14 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 9% |
| Chemistry | 3 | 3% |
| Other | 9 | 9% |
| Unknown | 26 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2015.
All research outputs
#15,746,007
of 24,003,070 outputs
Outputs from The Pharmacogenomics Journal
#584
of 854 outputs
Outputs of similar age
#206,203
of 360,164 outputs
Outputs of similar age from The Pharmacogenomics Journal
#9
of 15 outputs
Altmetric has tracked 24,003,070 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 854 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,164 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.